Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction
AssigneeAstraZeneca AB
InventorsLars Magnus Andersson, Tomas Lars-Gunnar Andersson, Olof Fredrik Bengtsson, Hans Peter Held, Garnet Edward Howells, Eva Christina Jensen, Robert Storey
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods for reducing the rate of cardiovascular death, myocardial infarction, or stroke in a patient in recognized need thereof, comprising administering to the patient a pharmaceutical composition comprising 60 mg ticagrelor twice daily.
Claims21
A method for reducing the rate of a composite endpoint of cardiovascular death, myocardial infarction, or stroke in a patient in recognized need thereof, comprising administering to the patient twice daily a pharmaceutical composition comprising 60 mg ticagrelor and a pharmaceutically acceptable carrier;
- wherein the patient has a history of myocardial infarction;
- wherein the patient is also administered a daily maintenance dose of aspirin of 75 mg to 150 mg;
- and
- wherein the rate of the composite endpoint in the patient is reduced relative to a dosing regimen where the patient receives the daily maintenance dose of aspirin of 75 mg to 150 mg only.
A method for reducing the rate of a composite endpoint of cardiovascular death, myocardial infarction, or stroke in a patient in recognized need thereof, comprising administering to the patient twice daily a pharmaceutical composition comprising 60 mg ticagrelor and a pharmaceutically acceptable carrier;
- wherein the patient has or had acute coronary syndrome;
- wherein the patient is also administered a daily maintenance dose of aspirin of 75 mg to 150 mg;
- and
- wherein the rate of the composite endpoint in the patient is reduced relative to a dosing regimen where the patient receives the daily maintenance dose of aspirin of 75 mg to 150 mg only.
Dependencies are inferred from the claim text.